Trials / Completed
CompletedNCT04990037
A Study of the Safety and Tolerance of CAN04 in Combination With FOLFIRINOX in Subjects With Metastatic Pancreatic Ductal Adenocarcinoma
A Phase 1b Dose Escalation and Expansion Study of CAN04, a Monoclonal Antibody Targeting IL1RAP, in Combination With Modified FOLFIRINOX in Subjects With Metastatic Pancreatic Ductal Adenocarcinoma
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 25 (actual)
- Sponsor
- Cantargia AB · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study will consider the safety and effectiveness of a study drug, CAN04, in combination with FOLFIRINOX, in the treatment of metastatic pancreatic ductal adenocarcinoma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | CAN04 | Administered intravenously |
| DRUG | FOLFIRINOX | Administered intravenously |
Timeline
- Start date
- 2021-07-19
- Primary completion
- 2023-05-30
- Completion
- 2023-06-15
- First posted
- 2021-08-04
- Last updated
- 2023-06-29
Locations
9 sites across 2 countries: France, Spain
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04990037. Inclusion in this directory is not an endorsement.